Last updated on February 2018

Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies


Brief description of study

This study is a Phase 1, Non-randomized, Open-label/Phase 2 Randomized, Blinded Study of ProTmune (ex vivo programmed mobilized peripheral blood cells) Versus Non-programmed mobilized peripheral blood cells for Allogeneic Hematopoietic Cell Transplantation (HCT) in Adult Subjects Aged 18 to 70 years with Hematologic Malignancies. A maximum of 70 total eligible subjects will be enrolled and treated in the trial at approximately 15-20 centers in the US and EU.

Clinical Study Identifier: NCT02743351

Contact Investigators or Research Sites near you

Start Over

Chatchada Karanes, MD

City of Hope
Duarte, CA United States
  Connect »

John R Edwards, MD

Indiana Blood and Marrow Transplant
Indianapolis, IN United States
  Connect »

Abhinav Deol, MD

Barbara Ann Karmanos Cancer Institute
Detroit, MI United States
  Connect »

Carlos Bachier, MD

Sarah Cannon Research Institute
Nashville, TN United States
  Connect »

John McCarty, MD

Virginia Commonwealth University
Richmond, VA United States
  Connect »

Ayman Saad, MD

University of Alabama
Birmingham, AL United States
  Connect »

Dimitrios Tzachanis, MD

University of California, San Diego (UCSD) Moores Cancer Center
San Diego, CA United States
  Connect »

Michael Bishop

University of Chicago
Chicago, IL United States
  Connect »

Corey Cutler, MD

Dana Farber Cancer Institute
Boston, MA United States
  Connect »

Koen Van Besien, MD

Weill Cornell Medicine
New York, NY United States
  Connect »

James Essell, MD

Jewish Hospital
Cincinnati, OH United States
  Connect »

Richard Maziarz, MD

Oregon Health & Science University
Portland, OR United States
  Connect »

Cesar Freytes, MD

Texas Transplant Institute
San Antonio, TX United States
  Connect »

Daniel Couriel, MD

Huntsman Cancer Institute (University of Utah)
Salt Lake City, UT United States
  Connect »